Resected pancreatic adenocarcinoma: An Asian institution's experience
Authors:
- Kennedy Yao Yi NgKNKennedy Yao Yi Ng
- Edwin Wei Xiang ChowECEdwin Wei Xiang Chow
- Bochao JiangBJBochao Jiang
- Cindy LimCLCindy Lim
- Brian Kim Poh GohBGBrian Kim Poh Goh
- Jin Yao TeoJTJin Yao Teo
- Damien Meng Yew TanDTDamien Meng Yew Tan
- Peng Chung CheowPCPeng Chung Cheow
- London Lucien Peng Jin OoiLOLondon Lucien Peng Jin Ooi
- Pierce Kah Hoe ChowPCPierce Kah Hoe Chow
- Joycelyn Jie Xin LeeJLJoycelyn Jie Xin Lee
Open Access
- 3 May 2021
- journal article
- research article
- Published by Wiley in Cancer Reports
- Vol. 4 (5) , e1393
Abstract
Background: Pancreatic adenocarcinoma (PDAC) is highly lethal. Surgery offers the only chance of cure, but 5‐year overall survival (OS) after surgical resection and adjuvant therapy remains dismal. Adjuvant trials were mostly conducted in the West enrolling fit patients. Applicability to a general population, especially Asia has not been described adequately.Aim: We aimed to evaluate the clinical outcomes, prognostic factors of survival, pattern, and timing of recurrence after curative resection in an Asian institution.Methods and Results: The clinicopathologic and survival outcomes of 165 PDAC patients who underwent curative resection between 1998 and 2013 were reviewed retrospectively. Median age at surgery was 62.0 years. 55.2% were male, and 73.3% had tumors involving the head of pancreas. The median OS of the entire cohort was 19.7 months. Median OS of patients who received adjuvant chemotherapy was 23.8 months. Negative predictors of survival include lymph node ratio (LNR) of >0.3 (HR = 3.36, P = .001), tumor site involving the body or tail of pancreas (HR = 1.59, P = .046), presence of perineural invasion (PNI) (HR = 2.36, P = .018) and poorly differentiated/undifferentiated tumor grade (HR = 1.86, P = .058). The median time to recurrence was 8.87 months, with 66.1% and 81.2% of patients developing recurrence at 12 months and 24 months respectively. The most common site of recurrence was the liver.Conclusion: The survival of Asian patients with resected PDAC who received adjuvant chemotherapy is comparable to reported randomized trials. Clinical characteristics seem similar to Western patients. Hence, geographical locations may not be a necessary stratification factor in RCTs. Conversely, lymph node ratio and status of PNI ought to be incorporated.Keywords
This publication has 63 references indexed in Scilit:
- Perineural invasion and associated pain in pancreatic cancerNature Reviews Cancer, 2011
- Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three DecadesAnnals of Surgical Oncology, 2011
- Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III TrialAnnals of Surgical Oncology, 2011
- Impact of Tumor Grade on Prognosis in Pancreatic Cancer: Should We Include Grade in AJCC Staging?Annals of Surgical Oncology, 2010
- Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative StudyAnnals of Surgical Oncology, 2010
- Does the Mechanism of Lymph Node Invasion Affect Survival in Patients with Pancreatic Ductal Adenocarcinoma?Journal of Gastrointestinal Surgery, 2009
- Long-Term Survival After Multidisciplinary Management of Resected Pancreatic AdenocarcinomaAnnals of Surgical Oncology, 2009
- The anatomic location of pancreatic cancer is a prognostic factor for survivalHPB, 2008
- Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic AdenocarcinomaAnnals of Surgery, 2007
- Prognostic Nomogram for Patients Undergoing Resection for Adenocarcinoma of the PancreasAnnals of Surgery, 2004